Pfizer Says COVID-19 Vaccine Shows ‘100% Efficacy’ In Adolescents

Pfizer states its COVID-19 vaccine is revealed to be exceptionally effective in young teenagers.

Esteban Felix/AP

conceal caption

toggle caption

Esteban Felix/AP

Pfizer says its COVID-19 vaccine is shown to be very reliable in young teenagers.

Esteban Felix/AP

Currently, the Pfizer-BioNTech vaccine is licensed for usage only in people who are at least 16. The business, which developed the vaccine together, are working to check it in kids as young as 6 months. In the first part of that study, a group of kids from 5 to 11 years old got their first shots last week.

During the clinical trial, 18 people who were in the placebo group established COVID-19, while none of individuals in the vaccinated group did. Blood tests showed a strong body immune system response one month after participants got the second vaccine dose, according to a summary of test information released by Pfizer.

Presently, the Pfizer-BioNTech vaccine is licensed for usage only in people who are at least 16. The companies, which established the vaccine together, are working to check it in children as young as 6 months.

Pfizer will submit the data “in the coming weeks,” Pfizer CEO and Chairman Albert Bourla stated in a press release about the trial. Calling the outcomes motivating, he added that the business is acting “with the hope of beginning to immunize this age group prior to the start of the next school year.”

Pfizer and its vaccine partner BioNTech say they will send the results “as quickly as possible” to the U.S. Food and Drug Administration and the European Medicines Agency, asking regulators to broaden their permissions for the vaccines usage in young individuals.

When it comes to prospective side effects, Pfizer stated the vaccine was tolerated well in the Phase 3 trial.

New scientific trials showed that Pfizers COVID-19 vaccine generates “100% efficacy and robust antibody responses” in adolescents from 12-15 years old, the drug business revealed Wednesday. The trial included 2,260 trial participants; the outcomes are even better than earlier actions from individuals ages 16-25.